nderstanding Extracorporal Membrane Oxygenation Induced Coaguloapathy – A Prospective Cohort Study in the Intensive Care Unit (EXTRICATE) - EXTRICATE

niversität Witten/Herdecke & Klinik Köln Merheim0 个研究点目标入组 50 人开始时间: 2024年2月29日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•For VV-ECMO analogous to previous studies:
•- severe ARDS according to the Berlin criteria
•- PaO2:FiO2 ratio <50 mmHg for >3 hours despite optimization of mechanical ventilation [FiO2 =80%, tidal volume = 6 ml per kg of ideal body weight and positive end-expiratory pressure (PEEP) =10 cm H2O) and despite the use of adjuvant therapeutic measures (e.g. inhaled nitric oxide therapy, recruitment maneuver, ventilation in prone position)]
•- PaO2:FIO2 ratio <80 mmHg for >6 hours despite the aforementioned measures
•- Arterial pH <7.25 with PaCO2 >60 mmHg for >6 hours under ventilator settings with a plateau pressure =32 cm H2O
•For VA-ECMO analogous to previous studies:
•- Observed collapse with no-flow time < 5 min and low-flow time < 90 min on arrival in the cardiac catheter
•- Initial and sustained defibrillable rhythm or non-defibrillable rhythm in case of tamponade or pulmonary artery embolism (exception: accidental hypothermia or intoxication)

•1. pregnancy
•2. patient moribund or with Simplified Acute Physiology Score value >90
•3. underlying malignancy with life expectancy < 5 years
•4. irreversible neurological damage
•5. decision to limit therapy
•6. ventilation for longer than 7 days (for vv-ECMO)
•7. chronic lung disease and chronic respiratory respiratory insufficiency with home oxygen therapy (for vv-ECMO)
•8. history of heparin-induced thrombocytopenia or other contraindication to heparin
•9. hereditary thrombophilia or hemophilia
•10. therapeutic anticoagulation or dual platelet inhibition

发起方

niversität Witten/Herdecke & Klinik Köln Merheim